# Peptides for Dry Eye & Ocular-Surface Repair: The Honest Evidence Review

> Thymosin beta-4 (RGN-259) is the rare peptide with real, large human RCTs for the ocular surface — yet every pivotal Phase 3 missed its co-primary endpoint. A clinical-editorial ranking of what the dry-eye evidence actually supports in 2026.

*Published 2026-07-01 · Updated 2026-07-01 · By Elena Soto, PharmD*

The short answer
For dry eye, the peptide story is essentially one molecule: **thymosin beta-4 (Tβ4), formulated as the eye drop RGN-259 (timbetasin)**. Unlike most 'healing' peptides, it was tested in multiple large, randomized, double-masked, placebo-controlled human trials — yet **every pivotal Phase 3 missed its pre-specified co-primary endpoint**, while showing consistent secondary-endpoint benefit and an excellent safety profile across >1,700 subjects. Honest grade for dry eye: **B** — real signal, no clean win, no FDA approval.[5](https://peptidevox.com/#r5)[1](https://peptidevox.com/#r1)

*This is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Eye medicine is unforgiving: the cornea is delicate, sterile compounding is non-trivial, and self-administered or grey-market eye drops carry real risks of infection and injury. No peptide discussed here is FDA-approved for dry eye disease. Dosing figures, where mentioned, are reported strictly as seen in the literature. Decisions about ocular-surface disease belong with a qualified ophthalmologist or optometrist.*

Dry eye disease is a chronic, multifactorial disorder of the tear film and ocular surface, driven by tear instability, hyperosmolarity, inflammation, and epithelial damage. A functional, root-cause view treats the visible symptoms — grittiness, burning, fluctuating vision — as downstream of two repairable problems: a damaged corneal and conjunctival epithelium, and an inflamed, poorly lubricated surface. Most approved drugs target inflammation or tear production; far fewer directly accelerate healing of the epithelial surface, which is exactly the gap a regenerative peptide would fill. You can check for active ocular-surface peptide trials directly at [ClinicalTrials.gov](https://clinicaltrials.gov/).[8](https://peptidevox.com/#r8)

## Why would a peptide help dry eye at all?

Thymosin beta-4 is interesting precisely because it is a regenerative and repair molecule rather than a pure anti-inflammatory. It is a naturally occurring 43-amino-acid peptide whose best-characterized action is sequestering G-actin, which regulates the cytoskeletal machinery cells use to migrate.[8](https://peptidevox.com/#r8) Its proposed ocular mechanisms, drawn from cell and animal work, include promoting corneal epithelial cell migration and wound closure — the dominant mechanism behind the neurotrophic-keratopathy work — plus cytoprotection and anti-apoptosis, anti-inflammatory activity, and restoration of tear-film and surface quality.[6](https://peptidevox.com/#r6) In a mouse dry-eye model, Tβ4 increased tear production, improved corneal smoothness, reduced fluorescein staining, and supported goblet-cell and mucin recovery, scoring active across all measured parameters where cyclosporine, diquafosol, and lifitegrast each missed several.[8](https://peptidevox.com/#r8)

The honesty caveat on mechanism is decisive: a clean mechanistic story and strong animal data are exactly what make a molecule worth a Phase 3 trial — they do not constitute proof it works in patients. That preclinical comparison study was also conducted by authors with financial ties to the developer and used very small group sizes (roughly four to five per group), so it is best read as hypothesis-supporting, not confirmatory.[8](https://peptidevox.com/#r8)

## How do the options rank for dry eye specifically?

The honest hierarchy for dry eye ranks by evidence strength multiplied by dry-eye relevance, putting completed human-outcome data above preclinical signal and a clean pivotal win above secondary-endpoint benefit. The table below summarizes where each option stands.

  Dry-eye peptide (and benchmark) evidence at a glance (2026)

    OptionBest evidence for dry eyeGrade

    Thymosin beta-4 (RGN-259 eye drop)Three Phase 3 dry-eye RCTs — co-primary endpoints missed, secondary endpoints significant; >1,700 subjectsB
    Cenegermin (Oxervate)FDA-approved biologic with a clean pivotal RCT — but for neurotrophic keratitis, NOT dry eyeA (NK, not dry eye)
    Standard dry-eye careControlled human trials + approved anti-inflammatory/tear-support therapyA
    Injectable TB-500No human or animal ocular-surface evidence; wrong formulation; WADA-bannedD

**RGN-259** is the only peptide with a genuine human ocular-surface program. An early Phase 2 trial in severe dry eye including graft-versus-host disease reported about a 35% reduction in ocular discomfort (p=0.0141) and about a 59% reduction in total corneal fluorescein staining (p=0.0108) versus vehicle, with benefit persisting after stopping.[1](https://peptidevox.com/#r1) A controlled-adverse-environment Phase 2 trial in 72 subjects then missed its co-primary endpoints but hit secondary ones, including a roughly 27% reduction in discomfort (p=0.0244) and significant corneal-staining improvements.[2](https://peptidevox.com/#r2)[3](https://peptidevox.com/#r3) The larger ARISE program followed the same pattern: ARISE-1 (317 patients) missed its primaries but produced dose-dependent signal-finding results, and ARISE-2 and ARISE-3 both failed their pre-specified co-primary endpoints while pooled analysis showed significant benefit on central corneal staining (pooled p=0.0074).[4](https://peptidevox.com/#r4)[5](https://peptidevox.com/#r5) In neurotrophic keratopathy, the US SEER-1 Phase 3 narrowly missed complete healing at Day 29 (6/10 vs 1/8, p=0.0656) but showed significant durable healing at Day 43 (5/10 vs 0/8, p=0.0359), while the European SEER-3 failed on a strong placebo response.[6](https://peptidevox.com/#r6)[7](https://peptidevox.com/#r7)

**Cenegermin (Oxervate)** is the evidentiary benchmark: an FDA-approved recombinant nerve-growth-factor biologic with about 70% complete corneal healing versus about 28% on vehicle across two eight-week RCTs — but approved for neurotrophic keratitis, not ordinary dry eye, and obtained by specialist prescription rather than bought online.[10](https://peptidevox.com/#r10)[11](https://peptidevox.com/#r11) **Standard dry-eye care** — tear-film support and approved anti-inflammatory drops under specialist oversight — remains the honest, accessible first line while the peptide stays investigational. **Injectable TB-500**, by contrast, is a synthetic fragment sold for systemic injection with zero ocular-surface evidence; it is a cautionary contrast, not a therapy.[14](https://peptidevox.com/#r14)

## What does the evidence NOT support?

It does not support that peptides cure dry eye: no peptide is FDA-approved for dry eye, and the most-tested candidate missed its pivotal Phase 3 co-primary endpoints in three separate trials.[5](https://peptidevox.com/#r5) It does not support injecting TB-500 or similar fragments to heal the eyes: there is no ocular-surface trial evidence for systemic peptide injections in dry eye, and injectable TB-500 is a different formulation from the studied eye drop.[14](https://peptidevox.com/#r14) It does not support compounded peptide eye drops as a safe shortcut to the trial drug, because the favorable safety record belongs to the sterile, pharmaceutical-grade trial formulation, not to compounded or research-chemical drops, and TB-500 sits as a 503A Category 2 bulk substance not endorsed for compounding.[12](https://peptidevox.com/#r12)[13](https://peptidevox.com/#r13) And it does not support that RGN-259 works as well as or better than approved drugs in patients — that head-to-head claim rests on a mouse model, not a human comparative trial.[8](https://peptidevox.com/#r8)

## What are the safety, legal, and sport-eligibility risks?

In its sterile trial formulation, RGN-259 was repeatedly described as well-tolerated across more than 1,700 subjects, with only mild-to-moderate adverse events comparable to placebo, no drug-related serious adverse events, and no signal on intraocular pressure, visual acuity, or corneal sensitivity; the preservative-free formulation is favorable for chronic ocular-surface use.[5](https://peptidevox.com/#r5)[6](https://peptidevox.com/#r6) That reassuring record does not extend to grey-market, research-use-only, or compounded peptide eye drops, which risk microbial keratitis and permanent corneal damage; the eye has no margin for contamination.

On regulatory status, thymosin beta-4 and RGN-259 are not FDA-approved for dry eye, neurotrophic keratopathy, or any indication, despite completed Phase 3 trials and an FDA orphan-drug designation for neurotrophic keratopathy.[9](https://peptidevox.com/#r9) TB-500 is not FDA-approved for any human use and, as of early 2026, is a 503A Category 2 bulk drug substance not eligible for routine compounding, with a Pharmacy Compounding Advisory Committee peptide review actively in flux.[12](https://peptidevox.com/#r12)[13](https://peptidevox.com/#r13) For athletes and service members, thymosin beta-4 and TB-500 are prohibited at all times under the 2026 WADA Prohibited List, regardless of route, amount, or timing — relevant even to a tested athlete considering an investigational eye drop.[14](https://peptidevox.com/#r14)

**Bottom line.** If you want a peptide with real human trial data for the ocular surface, thymosin beta-4 / RGN-259 is the only serious candidate — and even it has not cleared the FDA bar, missing every pivotal co-primary endpoint while showing a consistent secondary-endpoint signal. The one approved regenerative ocular-surface drug, cenegermin, is a biologic for neurotrophic keratitis, not dry eye. Graded honestly, the peptide-for-dry-eye category tops out at B in 2026, and regulatory facts here — including the pending PCAC peptide review — should be re-verified after mid-2026.

---
Source: https://peptidevox.com/injuries-and-orthopedics/peptides-for-dry-eye
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt